Cargando…
Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Autores principales: | Chen, Shuchun, Yu, Seong-Jin, Li, Yazhou, Lecca, Daniela, Glotfelty, Elliot, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Greig, Nigel H., Kim, Dong Seok, Wang, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135809/ https://www.ncbi.nlm.nih.gov/pubmed/30209317 http://dx.doi.org/10.1038/s41598-018-31455-w |
Ejemplares similares
-
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018) -
PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
por: Yu, Seong-Jin, et al.
Publicado: (2020) -
Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
por: Eakin, Katharine, et al.
Publicado: (2013) -
Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
por: Kim, Jeongah, et al.
Publicado: (2018) -
Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)